Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1937]

T cell therapy leading to prolonged remission for children with aggressive...

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA

T cell therapy leading to prolonged remission for children with aggressive leukaemia ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

ASH 2014: Expert discussion on the latest in AML

Prof Alan Burnett and Prof Sergio Amadori

ASH 2014: Expert discussion on the latest in AML ( Prof Alan Burnett and Prof Sergio Amadori )

Pembrolizumab may bring hope for patients with Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Pembrolizumab may bring hope for patients with Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Immunology highlights from ASH 2014

Dr Catherine Bollard - George Washington University, Washington, USA

Immunology highlights from ASH 2014 ( Dr Catherine Bollard - George Washington University, Washington, USA )

Comment: T cell therapy for children with aggressive leukaemia

Dr Catherine Bollard - George Washington University, Washington, USA

Comment: T cell therapy for children with aggressive leukaemia ( Dr Catherine Bollard - George Washington University, Washington, USA )

Comment: Blinatumomab for acute lymphocytic leukaemia

Dr Catherine Bollard - George Washington University, Washington, USA

Comment: Blinatumomab for acute lymphocytic leukaemia ( Dr Catherine Bollard - George Washington University, Washington, USA )

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma

Dr Catherine Bollard - George Washington University, Washington, USA

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma ( Dr Catherine Bollard - George Washington University, Washington, USA )

ASH 2014: Expert discussion on the latest in CLL

Prof John Gribben and Prof Stephan Stilgenbauer

ASH 2014: Expert discussion on the latest in CLL ( Prof John Gribben and Prof Stephan Stilgenbauer )

Engineering stem cell resistance to HIV for two-pronged approach to HIV...

Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA

Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma ( Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA )

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive...

Dr Thomas Martin, MD, University of California, San Francisco, USA

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma ( Dr Thomas Martin, MD, University of California, San Francisco, USA )

Investigational antibody demonstrates efficacy, safety for patients with...

Dr Thomas Martin, MD, University of California, San Francisco, USA

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study ( Dr Thomas Martin, MD, University of California, San Francisco, USA )

More from ecancer